Bli medlem
Bli medlem

Du är här


Swedish Orphan Biovitrum AB (publ): Kineret® receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis

Swedish Orphan Biovitrum AB(publ) (Sobi) together with its Australian partner,
A. Menarini Australia Pty Ltd received marketing authorisation in Australia
for Kineret (anakinra) for the treatment of systemic juvenile idiopathic
arthritis (SJIA), which is a rare form of juvenile chronic arthritis.

"We are pleased and encouraged by this approval which was achieved through a
fruitful collaboration between physicians, regulators, and our development
team including Menarini," says Kristina Timdahl, Medical Therapeutic Area
Head for the business area Inflammation at Sobi, "We are looking forward to
serving a wider group of patients in Australia going forward."


About SJIA

Systemic juvenile idiopathic arthritis (SJIA) is a rare form of chronic
arthritis in children up to 16 years of age. About 100 of 100,000 children
are affected by child arthritis, and of these 10-20 percent have the sJIA
form, today classified as an autoinflammatory disease. The disease does not
only cause inflammation of the joints but also fever spikes, rash, anaemia,
and enlargement and inflammation of major organs. Despite treatment, many
children suffer life-long and serious complications such as osteoporosis and
stunted growth.

About Kineret

Kineret (anakinra) is a recombinant protein drug that blocks the biological
activity of IL-1a and IL -1b by binding to interleukin-1 type 1 receptor
(IL-R 1), expressed in a variety of tissues and organs, and thereby blocking
the interleukin-1 (IL-1) signalling. IL-1 is a key mediator of inflammation
and a significant contributor to autoinflammatory diseases.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on
NASDAQ OMX Stockholm. More information is available

About A.Menarini Australia

A member of the Menarini Group, a leading European biopharmaceutical company,
Menarini Australia is focused on delivering differentiated ethical and
consumer healthcare brands to Australians. With an extensive brand portfolio,
Menarini Australia markets a wide range of pharmaceutical, biotechnology and
consumer health brands. Building on our strengths in dermatology, primary
care, consumer health and specialty care, Menarini Australia is now
introducing new products in men's sexual health, cardiovascular and
allergy/respiratory therapeutic areas. For further information please

For more information please contact

| Sobi |
| Media relations Investor relations |
| Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| |

030e_Sobi SJIA Australia


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.